Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Anti-Mullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.

Finkelstein JS, Lee H, Karlamangla A, Neer RM, Sluss PM, Burnett-Bowie SM, Darakananda K, Donahoe PK, Harlow SD, Prizand SH, Joffe H, Kumar A, Martin DE, McConnell D, Merrilat S, Morrison A, Pastore LM, Randolph JF, Greendale GA, Santoro N.

J Clin Endocrinol Metab. 2020 Jan 22. pii: dgz283. doi: 10.1210/clinem/dgz283. [Epub ahead of print]

PMID:
31965189
2.

Anthropometric and Biochemical Correlates of PAPP-A2, Free IGF-I, and IGFBP-3 in Childhood.

Fujimoto M, Khoury JC, Khoury PR, Kalra B, Kumar A, Sluss P, Oxvig C, Hwa V, Dauber A.

Eur J Endocrinol. 2020 Jan 1. pii: EJE-19-0859.R1. doi: 10.1530/EJE-19-0859. [Epub ahead of print]

PMID:
31961798
3.

Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis.

Dichtel LE, Schorr M, Loures de Assis C, Rao EM, Sims JK, Corey KE, Kohli P, Sluss PM, McPhaul MJ, Miller KK.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4827-4836. doi: 10.1210/jc.2019-00022.

PMID:
31009049
4.

Estradiol reference intervals in women during the menstrual cycle, postmenopausal women and men using an LC-MS/MS method.

Verdonk SJE, Vesper HW, Martens F, Sluss PM, Hillebrand JJ, Heijboer AC.

Clin Chim Acta. 2019 Aug;495:198-204. doi: 10.1016/j.cca.2019.04.062. Epub 2019 Apr 11.

PMID:
30981845
5.

Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation.

Fujimoto M, Andrew M, Liao L, Zhang D, Yildirim G, Sluss P, Kalra B, Kumar A, Yakar S, Hwa V, Dauber A.

Endocrinology. 2019 Jun 1;160(6):1363-1376. doi: 10.1210/en.2018-00755.

PMID:
30977789
6.

Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.

Clendenen TV, Ge W, Koenig KL, Afanasyeva Y, Agnoli C, Brinton LA, Darvishian F, Dorgan JF, Eliassen AH, Falk RT, Hallmans G, Hankinson SE, Hoffman-Bolton J, Key TJ, Krogh V, Nichols HB, Sandler DP, Schoemaker MJ, Sluss PM, Sund M, Swerdlow AJ, Visvanathan K, Zeleniuch-Jacquotte A, Liu M.

Breast Cancer Res. 2019 Mar 19;21(1):42. doi: 10.1186/s13058-019-1126-z.

7.

The Relationship Between Progesterone, Sleep, and LH and FSH Secretory Dynamics in Early Postmenarchal Girls.

Sun BZ, Kangarloo T, Adams JM, Sluss P, Chandler DW, Zava DT, McGrath JA, Umbach DM, Shaw ND.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2184-2194. doi: 10.1210/jc.2018-02400.

8.

Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity.

Sun BZ, Kangarloo T, Adams JM, Sluss PM, Welt CK, Chandler DW, Zava DT, McGrath JA, Umbach DM, Hall JE, Shaw ND.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):613-623. doi: 10.1210/jc.2018-00595.

9.

Do metabolites account for higher serum steroid hormone levels measured by RIA compared to mass spectrometry?

Stanczyk FZ, Xu X, Sluss PM, Brinton LA, McGlynn KA.

Clin Chim Acta. 2018 Sep;484:223-225. doi: 10.1016/j.cca.2018.05.054. Epub 2018 May 28.

PMID:
29852126
10.

Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Ge W, Clendenen TV, Afanasyeva Y, Koenig KL, Agnoli C, Brinton LA, Dorgan JF, Eliassen AH, Falk RT, Hallmans G, Hankinson SE, Hoffman-Bolton J, Key TJ, Krogh V, Nichols HB, Sandler DP, Schoemaker MJ, Sluss PM, Sund M, Swerdlow AJ, Visvanathan K, Liu M, Zeleniuch-Jacquotte A.

Int J Cancer. 2018 Jun 1;142(11):2215-2226. doi: 10.1002/ijc.31249. Epub 2018 Feb 8.

11.

Type 1 Diabetes - A Clinical Perspective.

Kahanovitz L, Sluss PM, Russell SJ.

Point Care. 2017 Mar;16(1):37-40. doi: 10.1097/POC.0000000000000125.

12.

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA, Egleston BL, Falk RT, Fortner RT, Helzlsouer KJ, Gao Y, Idahl A, Kaaks R, Krogh V, Merritt MA, Lundin E, Onland-Moret NC, Rinaldi S, Schock H, Shu XO, Sluss PM, Staats PN, Sacerdote C, Travis RC, Tjønneland A, Trichopoulou A, Tworoger SS, Visvanathan K, Weiderpass E, Zeleniuch-Jacquotte A, Dorgan JF.

Int J Cancer. 2018 Jan 15;142(2):262-270. doi: 10.1002/ijc.31058. Epub 2017 Oct 4.

13.

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.

Fortner RT, Schock H, Jung S, Allen NE, Arslan AA, Brinton LA, Egleston BL, Falk RT, Gunter MJ, Helzlsouer KJ, Idahl A, Johnson TS, Kaaks R, Krogh V, Lundin E, Merritt MA, Navarro C, Onland-Moret NC, Palli D, Shu XO, Sluss PM, Staats PN, Trichopoulou A, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Br J Cancer. 2017 Oct 24;117(9):1412-1418. doi: 10.1038/bjc.2017.299. Epub 2017 Sep 5.

14.

Oxytocin secretion is pulsatile in men and is related to social-emotional functioning.

Baskaran C, Plessow F, Silva L, Asanza E, Marengi D, Eddy KT, Sluss PM, Johnson ML, Misra M, Lawson EA.

Psychoneuroendocrinology. 2017 Nov;85:28-34. doi: 10.1016/j.psyneuen.2017.07.486. Epub 2017 Jul 24.

15.

Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Jung S, Allen N, Arslan AA, Baglietto L, Brinton LA, Egleston BL, Falk R, Fortner RT, Helzlsouer KJ, Idahl A, Kaaks R, Lundin E, Merritt M, Onland-Moret C, Rinaldi S, Sánchez MJ, Sieri S, Schock H, Shu XO, Sluss PM, Staats PN, Travis RC, Tjønneland A, Trichopoulou A, Tworoger S, Visvanathan K, Krogh V, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Fertil Steril. 2017 Apr;107(4):1012-1022.e2. doi: 10.1016/j.fertnstert.2017.02.105.

16.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH.

Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.

17.

Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome.

Bui HN, Sluss PM, Hayes FJ, Blincko S, Knol DL, Blankenstein MA, Heijboer AC.

Clin Chim Acta. 2015 Oct 23;450:227-32. doi: 10.1016/j.cca.2015.08.019. Epub 2015 Aug 29.

PMID:
26327459
18.

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.

Styer AK, Gaskins AJ, Brady PC, Sluss PM, Chavarro JE, Hauser RB, Toth TL.

Fertil Steril. 2015 Nov;104(5):1153-61.e1-7. doi: 10.1016/j.fertnstert.2015.07.1161. Epub 2015 Aug 24.

PMID:
26315051
19.

Compensatory Increase in Ovarian Aromatase in Older Regularly Cycling Women.

Shaw ND, Srouji SS, Welt CK, Cox KH, Fox JH, Adams JA, Sluss PM, Hall JE.

J Clin Endocrinol Metab. 2015 Sep;100(9):3539-47. doi: 10.1210/JC.2015-2191. Epub 2015 Jun 30.

20.

A Call to Standardize Preanalytic Data Elements for Biospecimens, Part II.

Robb JA, Bry L, Sluss PM, Wagar EA, Kennedy MF; College of American Pathologists Diagnostic Intelligence and Health Information Technology Biorepository Working Group 2.

Arch Pathol Lab Med. 2015 Sep;139(9):1125-8. doi: 10.5858/arpa.2014-0572-CP. Epub 2015 Jan 16.

PMID:
25594725
21.

Analysis of VEGF/PlGF heterodimer level in pancreatic cyst fluid as a biomarker for serous cystadenoma.

Wu RI, Sluss PM, Mino-Kenudson M, Brugge WR, Pitman MB.

J Am Soc Cytopathol. 2015 Mar - Apr;4(2):79-83. doi: 10.1016/j.jasc.2014.09.205. Epub 2014 Sep 10.

PMID:
31051713
22.

Editorial: the new instructions to authors for the reporting of steroid hormone measurements.

Wierman ME, Auchus RJ, Haisenleder DJ, Hall JE, Handelsman D, Hankinson S, Rosner W, Singh RJ, Sluss PM, Stanczyk FZ.

Endocrinology. 2014 Dec;155(12):4603. doi: 10.1210/en.2014-1735. Epub 2014 Oct 29. No abstract available.

PMID:
25354305
23.

Editorial: The new instructions to authors for the reporting of steroid hormone measurements.

Wierman ME, Auchus RJ, Haisenleder DJ, Hall JE, Handelsman D, Hankinson S, Rosner W, Singh RJ, Sluss PM, Stanczyk FZ.

J Clin Endocrinol Metab. 2014 Dec;99(12):4375. doi: 10.1210/jc.2014-3424. No abstract available.

PMID:
25354278
24.

Editorial: The new instructions to authors for the reporting of steroid hormone measurements.

Wierman ME, Auchus RJ, Haisenleder DJ, Hall JE, Handelsman D, Hankinson S, Rosner W, Singh RJ, Sluss PM, Stanczyk FZ.

Endocr Rev. 2014 Dec;35(6):849. doi: 10.1210/er.2014-1067. Epub 2014 Oct 29. No abstract available.

PMID:
25354232
25.

Editorial: the new instructions to authors for the reporting of steroid hormone measurements.

Wierman ME, Auchus RJ, Haisenleder DJ, Hall JE, Handelsman D, Hankinson S, Rosner W, Singh RJ, Sluss PM, Stanczyk FZ.

Mol Endocrinol. 2014 Dec;28(12):1917. doi: 10.1210/me.2014-1285. No abstract available.

26.

Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency.

Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, Gurel MH, Sluss PM, Biller BM, Miller KK.

J Clin Endocrinol Metab. 2014 Dec;99(12):4712-9. doi: 10.1210/jc.2014-2830.

27.

The practice of clinical pathology: a quantitative description of laboratory director activities at a large academic medical center.

Branda JA, Dighe AS, Dzik W, Ferraro MJ, Flood J, Lee-Lewandrowski E, Makar R, Mandokolathur M, Rosenberg ES, Saidman S, Sluss P, Sohani AR, Stowell C, Van Cott EM, Lewandrowski KB.

Am J Clin Pathol. 2014 Aug;142(2):144-9. doi: 10.1309/AJCP3NU7AOPPKYWO.

PMID:
25015853
28.

European, Middle Eastern, and African Society for Biopreservation and Biobanking (ESBB). 2012 Conference Session on Biobanking in Emerging Countries.

Lawlor RT, Sluss PM, Langer R, Sughayer MA, Igbe MA, Siddiqui K, De Blasio P, Duma B, Mendy M, Chabannon C, Ibrahim M.

Biopreserv Biobank. 2013 Jun;11(3):176-81. doi: 10.1089/bio.2013.0017. No abstract available.

PMID:
24850095
29.

Methodologies for measurement of cardiac markers.

Sluss PM.

Clin Lab Med. 2014 Mar;34(1):167-85, viii. doi: 10.1016/j.cll.2013.11.012. Review.

PMID:
24507795
30.

Preface to the special edition of Clin Chem Acta: utilization management in the clinical laboratory.

Lewandrowski K, Sluss P.

Clin Chim Acta. 2014 Jan 1;427:107-8. doi: 10.1016/j.cca.2013.11.011. No abstract available.

PMID:
24309229
31.

Evidence that increased ovarian aromatase activity and expression account for higher estradiol levels in African American compared with Caucasian women.

Shaw ND, Srouji SS, Welt CK, Cox KH, Fox JH, Adams JM, Sluss PM, Hall JE.

J Clin Endocrinol Metab. 2014 Apr;99(4):1384-92. doi: 10.1210/jc.2013-2398. Epub 2013 Nov 27.

32.

Reference laboratory utilization management.

Sluss PM.

Clin Chim Acta. 2014 Jan 1;427:167-72. doi: 10.1016/j.cca.2013.09.035. Epub 2013 Oct 15.

PMID:
24140173
33.

The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.

Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1961-6. doi: 10.1210/jc.2013-2410. Epub 2013 Sep 30.

34.

Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism.

Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Sluss PM, Crowley WF Jr, Pitteloud N.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1790-5. doi: 10.1210/jc.2013-2518. Epub 2013 Sep 13.

35.

A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.

Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE.

Cancer Res. 2013 Aug 1;73(15):4810-9. doi: 10.1158/0008-5472.CAN-13-0665. Epub 2013 Jun 19.

36.

Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL.

Eur J Heart Fail. 2013 Oct;15(10):1157-63. doi: 10.1093/eurjhf/hft075. Epub 2013 May 10.

37.

Challenges to the measurement of estradiol: an endocrine society position statement.

Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME.

J Clin Endocrinol Metab. 2013 Apr;98(4):1376-87. doi: 10.1210/jc.2012-3780. Epub 2013 Mar 5. Review.

38.

Pure T3-thyrotoxicosis from a Mexican weight loss supplement.

Daniels GH, Sluss P.

Endocr Pract. 2013 May-Jun;19(3):559-60. No abstract available.

PMID:
23425657
39.

Nocturnal oxytocin secretion is lower in amenorrheic athletes than nonathletes and associated with bone microarchitecture and finite element analysis parameters.

Lawson EA, Ackerman KE, Estella NM, Guereca G, Pierce L, Sluss PM, Bouxsein ML, Klibanski A, Misra M.

Eur J Endocrinol. 2013 Feb 20;168(3):457-64. doi: 10.1530/EJE-12-0869. Print 2013 Mar.

40.

Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay.

Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC.

Steroids. 2013 Jan;78(1):96-101. doi: 10.1016/j.steroids.2012.10.010. Epub 2012 Nov 2.

PMID:
23127814
41.

Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW + 10 Collaborative Group.

J Clin Endocrinol Metab. 2012 Apr;97(4):1159-68. doi: 10.1210/jc.2011-3362. Epub 2012 Feb 16.

42.

Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group.

Menopause. 2012 Apr;19(4):387-95. doi: 10.1097/gme.0b013e31824d8f40.

43.

Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW + 10 Collaborative Group.

Fertil Steril. 2012 Apr;97(4):843-51. doi: 10.1016/j.fertnstert.2012.01.128. Epub 2012 Feb 16.

44.

Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW+10 Collaborative Group.

Climacteric. 2012 Apr;15(2):105-14. doi: 10.3109/13697137.2011.650656. Epub 2012 Feb 16.

45.

Central hypothyroidism in a patient with pituitary autoimmunity: evidence for TSH-independent thyroid hormone synthesis.

Barbesino G, Sluss PM, Caturegli P.

J Clin Endocrinol Metab. 2012 Feb;97(2):345-50. doi: 10.1210/jc.2011-1591. Epub 2011 Nov 16.

46.

Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass.

Lawson EA, Donoho DA, Blum JI, Meenaghan EM, Misra M, Herzog DB, Sluss PM, Miller KK, Klibanski A.

J Clin Psychiatry. 2011 Nov;72(11):1546-51. doi: 10.4088/JCP.10m06617. Epub 2011 Aug 9.

47.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

48.

Estrogen levels are higher across the menstrual cycle in African-American women compared with Caucasian women.

Marsh EE, Shaw ND, Klingman KM, Tiamfook-Morgan TO, Yialamas MA, Sluss PM, Hall JE.

J Clin Endocrinol Metab. 2011 Oct;96(10):3199-206. doi: 10.1210/jc.2011-1314. Epub 2011 Aug 17.

49.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

50.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

Supplemental Content

Support Center